News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
56,241 Results
Type
Article (14997)
Company Profile (14)
Press Release (41223)
Multimedia
Podcasts (241)
Webinars (20)
Section
Business (22018)
Career Advice (904)
Deals (4027)
Drug Delivery (112)
Drug Development (7634)
Employer Resources (155)
FDA (1630)
Job Trends (2868)
News (31616)
Policy (3327)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (2)
Academia (406)
Academic (1)
Accelerated approval (14)
ADA (8)
Adcomms (15)
Allergies (18)
Alliances (4434)
ALS (31)
Alzheimer's disease (291)
Antibody-drug conjugate (ADC) (97)
Approvals (1368)
Artificial intelligence (203)
ASCO (49)
Autoimmune disease (32)
Automation (10)
Bankruptcy (57)
Best Places to Work (997)
BIO (9)
Biologics (1)
BIOSECURE Act (12)
Biosimilars (63)
BioSpace Insights (235)
Biotechnology (5)
Bladder cancer (14)
Brain cancer (12)
Breast cancer (44)
Cancer (531)
Cardiovascular disease (114)
Career advice (824)
Career pathing (43)
CAR-T (59)
CDC (34)
Celiac Disease (1)
Cell therapy (203)
Cervical cancer (9)
Clinical research (5527)
Collaboration (302)
Commercialization (3)
Company closure (5)
Compensation (52)
Complete response letters (33)
COVID-19 (497)
CRISPR (21)
C-suite (157)
Cystic fibrosis (23)
Data (387)
Decentralized trials (2)
Denatured (100)
Depression (54)
Dermatology (10)
Diabetes (81)
Diagnostics (661)
Digital health (11)
Diversity (10)
Diversity, equity & inclusion (40)
Drug discovery (126)
Drug pricing (92)
Drug shortages (24)
Duchenne muscular dystrophy (91)
Earnings (3958)
Editorial (59)
Employer branding (21)
Employer resources (130)
Events (5613)
Executive appointments (131)
FDA (1880)
Friedreich's ataxia (4)
Frontotemporal dementia (3)
Funding (338)
Gene editing (60)
Generative AI (36)
Gene therapy (212)
GLP-1 (449)
Government (928)
Grass and pollen (2)
Guidances (20)
Healthcare (1590)
Hematology (10)
HIV (16)
Huntington's disease (26)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (25)
Immunology and inflammation (127)
Immuno-oncology (19)
Indications (16)
Infectious disease (562)
Inflammatory bowel disease (31)
Inflation Reduction Act (11)
Influenza (5)
Intellectual property (26)
Interviews (144)
IPO (1036)
IRA (29)
Job creations (1665)
Job search strategy (678)
JPM (65)
Kidney cancer (2)
Labor market (123)
Layoffs (326)
Leadership (31)
Legal (801)
Licensing (3)
Liver cancer (10)
Longevity (11)
Lung cancer (82)
Lymphoma (15)
Machine learning (16)
Management (43)
Manufacturing (279)
Marketing (3)
MASH (35)
Medical affairs (1)
Medical device (1310)
Medtech (1325)
Mergers & acquisitions (3154)
Metabolic disorders (451)
mRNA (126)
Multiple sclerosis (14)
NASH (10)
Neurodegenerative disease (104)
Neuropsychiatric disorders (42)
Neuroscience (574)
Neurotech (1)
NextGen: Class of 2026 (1213)
Non-profit (358)
Now hiring (78)
Obesity (315)
Opinion (170)
Ovarian cancer (10)
Pain (38)
Pancreatic cancer (32)
Parkinson's disease (36)
Partnered (22)
Patents (60)
Patient recruitment (40)
Peanut (6)
People (6179)
Pharmaceutical (3)
Pharmacy benefit managers (6)
Phase 1 (1348)
Phase 2 (2173)
Phase 3 (2946)
Pipeline (755)
Policy (225)
Postmarket research (126)
Preclinical (531)
Press Release (5)
Prostate cancer (35)
Psychedelics (64)
Radiopharmaceuticals (74)
Rare diseases (342)
Real estate (2349)
Recruiting (58)
Regulatory (2466)
Reports (54)
Research institute (305)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (11)
RSV (16)
Schizophrenia (45)
Series A (74)
Series B (37)
Service/supplier (3)
Sickle cell disease (20)
Special edition (33)
Spinal muscular atrophy (25)
Sponsored (27)
Startups (947)
State (1)
Stomach cancer (6)
Supply chain (36)
Tariffs (30)
The Weekly (138)
Vaccines (303)
Venture capital (106)
Weight loss (268)
Women's health (41)
Worklife (21)
Date
Today (4)
Last 7 days (43)
Last 30 days (209)
Last 365 days (2572)
2026 (1758)
2025 (2696)
2024 (3288)
2023 (3508)
2022 (5179)
2021 (4914)
2020 (4222)
2019 (4327)
2018 (3360)
2017 (3720)
2016 (3724)
2015 (4102)
2014 (2424)
2013 (1236)
2012 (1206)
2011 (1394)
2010 (1013)
Location
Africa (310)
Alabama (6)
Arizona (23)
Arkansas (1)
Asia (3167)
Australia (626)
California (744)
Canada (235)
China (128)
Colorado (45)
Connecticut (35)
Delaware (14)
Europe (8858)
Florida (180)
Georgia (55)
Hawaii (1)
Idaho (8)
Illinois (140)
India (16)
Indiana (67)
Iowa (7)
Japan (45)
Kansas (12)
Kentucky (2)
Louisiana (3)
Maryland (76)
Massachusetts (721)
Michigan (39)
Minnesota (39)
Mississippi (2)
Missouri (10)
Montana (3)
Nebraska (6)
Nevada (15)
New Hampshire (6)
New Jersey (296)
New Mexico (3)
New York (224)
North Carolina (123)
North Dakota (2)
Northern California (322)
Ohio (19)
Oklahoma (3)
Oregon (8)
Pennsylvania (143)
Puerto Rico (2)
Rhode Island (8)
South America (313)
South Carolina (6)
Southern California (302)
Tennessee (20)
Texas (128)
United States (3095)
Utah (41)
Virginia (35)
Washington D.C. (13)
Washington State (64)
West Virginia (2)
Wisconsin (18)
56,241 Results for "chiesi farmaceutici spa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
April 14, 2026
·
1 min read
Press Releases
Chiesi Global Rare Diseases Highlights Advancements in Lipodystrophy Research at ENDO 2026
June 19, 2026
·
8 min read
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the rare genetic disorder hereditary angioedema.
April 29, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
June 11, 2026
·
8 min read
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.
July 27, 2026
·
3 min read
·
Gabrielle Masson
Press Releases
Chiesi Group Announces New Chair and Vice Chair
May 20, 2026
·
3 min read
Deals
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
April 12, 2023
·
3 min read
Press Releases
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
April 29, 2026
·
15 min read
Deals
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
January 8, 2023
·
12 min read
Press Releases
Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria
June 25, 2026
·
7 min read
1 of 5,625
Next
